BioXcel Therapeutics Celebrates Breakthrough in Neuroscience Innovation with Nasdaq Closing Bell Ceremony

BioXcel Therapeutics will ring the Nasdaq Stock Market Closing Bell on October 14 to celebrate its breakthrough progress in addressing unmet needs in psychiatry, specifically the treatment of agitation associated with bipolar disorders and schizophrenia. The honor marks the company's successful completion of its SERENITY At-Home pivotal trial and its commitment to patients and families affected by mental illness. The Nasdaq Closing Bell ceremony will take place at the Nasdaq MarketSite in New York and can be viewed live on the Nasdaq website.

BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company pioneering the use of artificial intelligence to develop transformative medicines in neuroscience, will ring the Nasdaq Stock Market Closing Bell on October 14, 2025. This honor marks a pivotal moment for the company, celebrating its breakthrough progress in addressing one of the most urgent unmet needs in psychiatry: the treatment of agitation associated with bipolar disorders and schizophrenia.

The Nasdaq Closing Bell ceremony will take place at the Nasdaq MarketSite, 4 Times Square, New York, beginning at 3:45 PM ET on October 14, 2025. The ceremony can be viewed live at [Nasdaq website]BioXcel Therapeutics to Ring Nasdaq Closing Bell on October 14 to Celebrate a Transformative Milestone in Neuroscience Innovation^[1].

The company's CEO, Vimal Mehta, Ph.D., and members of the BioXcel team will participate in the event. Mehta noted, "It is a profound honor to ring the Nasdaq closing bell on behalf of the entire BioXcel team. This moment reflects not only how far we’ve come as an organization but also our unwavering commitment to patients, families, and caregivers affected by mental illness. With the successful completion of our SERENITY At-Home pivotal trial, we are one step closer to our goal of redefining how agitation is managed and bringing IGALMI® directly to patients where they need it most: in the comfort and safety of their own homes."

BioXcel Therapeutics, Inc. is a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience. Its wholly owned subsidiary, OnkosXcel Therapeutics, is focused on the development of medicines in immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indications.

The company's SERENITY At-Home pivotal trial is a significant milestone, demonstrating the potential of AI-driven drug discovery in transforming the standard of care in neuropsychiatry. The trial's success highlights BioXcel's commitment to improving lives affected by mental illness.

The Nasdaq Closing Bell ceremony will be an opportunity to recognize BioXcel's achievements and the potential of its innovative approach to drug development. The ceremony is expected to attract attention from investors and financial professionals, as well as the broader public interested in mental health advancements.

References
BioXcel Therapeutics to Ring Nasdaq Closing Bell on October 14 to Celebrate a Transformative Milestone in Neuroscience Innovation^[1] https://www.stocktitan.net/news/BTAI/bio-xcel-therapeutics-to-ring-nasdaq-closing-bell-on-october-14-to-6yilfkcy1yon.html